TrialBlood cancer journal2021

Nivolumab maintenance in high-risk acute myeloid leukemia patients: a single-arm, open-label, phase II study.

Patrick K Reville et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.